Our Science

Our Programmes & Clinical Trials

Synairgen's primary focus is the development of its inhaled interferon-beta product candidate, SNG001, to meet the urgent need for the treatment of COVID-19 as potentially the first host-directed, broad-spectrum antiviral treatment delivered directly into the lungs. Pioneers of using ex vivo models, which use lung cells collected from patients with respiratory disease, the company is also exploring the use of SNG001 in other serious viral lung infections.